Nathalie Jette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nathalie Jette has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Ag Marson
1 shared publication- Anthony Guy Marson
Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK
1 shared publication Jan Claassen
1 shared publicationJane L Hutton
1 shared publicationJl Hutton
1 shared publicationK Hemming
1 shared publication
Latest Publications
- 16 July 2008
- Published by Wiley
- No. 3,p. CD001417
Topiramate add-on for drug-resistant partial epilepsy
The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies and up to 30% from clinical series (not population-based) develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy. To evaluate the efficacy and safety of topiramate when used as an add-on treatment for drug-resistant partial epilepsy. We searched the Cochrane Epilepsy Group Specialized Register (10 May 2007); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2007). No language restrictions were imposed. We also contacted the manufacturers of topiramate and researchers in the field to see any ongoing or published studies. Randomized placebo controlled add-on trials of topiramate recruiting people with drug-resistant partial epilepsy. Two review authors independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) side effects. Primary analyses were intention-to-treat. Summary relative risks (RR) with 95% confidence intervals (95% CI) are presented. Dose response was evaluated in regression models. Ten trials were included representing 1312 randomized participants. Baseline phases ranged from 4-12 weeks and double-blind phases from 11-19 weeks. The RR for a 50% or greater reduction in seizure frequency compared to placebo was 2.85 (95% CI 2.27 to 3.59). Dose regression analysis shows increasing effect with increasing dose, but found no advantage for doses over 300 or 400 mg per day. The RR for treatment withdrawal compared to placebo was 2.26 (95% CI 1.55 to 3.31). The RR for the following side effects indicate that they are significantly associated with topiramate: ataxia 1.95 (99% CI 1.04 to 3.65); dizziness 1.55 (99% CI 1.08 to 2.22); fatigue 2.19 (99% CI 1.43 to 3.35); nausea 2.35 (99% CI 1.28 to 4.29); somnolence 2.18 (99% CI 1.47 to 3.21) and 'thinking abnormally' 5.77 (99% CI 2.50 to 13.35). Topiramate has efficacy as an add-on treatment for drug-resistant partial epilepsy. However, trials reviewed were of relatively short duration, and provide no evidence for the long-term efficacy of topiramate. Results cannot be extrapolated to monotherapy or treating other epilepsy types.
- 16 July 2008
- Published by Wiley
- No. 3,p. CD001417
Topiramate add-on for drug-resistant partial epilepsy
The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies and up to 30% from clinical series (not population-based) develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy. To evaluate the efficacy and safety of topiramate when used as an add-on treatment for drug-resistant partial epilepsy. We searched the Cochrane Epilepsy Group Specialized Register (10 May 2007); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2007). No language restrictions were imposed. We also contacted the manufacturers of topiramate and researchers in the field to see any ongoing or published studies. Randomized placebo controlled add-on trials of topiramate recruiting people with drug-resistant partial epilepsy. Two review authors independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) side effects. Primary analyses were intention-to-treat. Summary relative risks (RR) with 95% confidence intervals (95% CI) are presented. Dose response was evaluated in regression models. Ten trials were included representing 1312 randomized participants. Baseline phases ranged from 4-12 weeks and double-blind phases from 11-19 weeks. The RR for a 50% or greater reduction in seizure frequency compared to placebo was 2.85 (95% CI 2.27 to 3.59). Dose regression analysis shows increasing effect with increasing dose, but found no advantage for doses over 300 or 400 mg per day. The RR for treatment withdrawal compared to placebo was 2.26 (95% CI 1.55 to 3.31). The RR for the following side effects indicate that they are significantly associated with topiramate: ataxia 1.95 (99% CI 1.04 to 3.65); dizziness 1.55 (99% CI 1.08 to 2.22); fatigue 2.19 (99% CI 1.43 to 3.35); nausea 2.35 (99% CI 1.28 to 4.29); somnolence 2.18 (99% CI 1.47 to 3.21) and 'thinking abnormally' 5.77 (99% CI 2.50 to 13.35). Topiramate has efficacy as an add-on treatment for drug-resistant partial epilepsy. However, trials reviewed were of relatively short duration, and provide no evidence for the long-term efficacy of topiramate. Results cannot be extrapolated to monotherapy or treating other epilepsy types.
- Open Access
- 1 December 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (12) , 1750-1755
Frequency and Predictors of Nonconvulsive Seizures During Continuous Electroencephalographic Monitoring in Critically Ill Children
The epidemiologic features and understanding of nonconvulsive seizures (NCSz) and status epilepticus (SE) in critically ill patients is limited. However, accumulating evidence demonstrates that NCSz and nonconvulsive status epilepticus (NCSE) occur frequently in critical care patients. It is estimated that 19% to 50% of patients undergoing continuous electroencephalographic monitoring (cEEG) in neurologic and neurosurgical intensive care units (ICUs) may be experiencing NCSz or NCSE,1-6 with many of the NCSz occurring after supposedly adequate treatment for generalized convulsive status epilepticus (GCSE).4,7 One prospective study evaluated comatose patients in all age groups with no overt clinical seizure activity to determine how many had NCSE, and 8% met the criteria for this diagnosis.8 One retrospective study at our center examined a population of 570 critically ill patients, 13% of whom were children.5 In that study, seizures were detected in 19% of patients who underwent cEEG, and these were exclusively nonconvulsive in 92%. Age younger than 18 years was a risk factor for electrographic seizures, with 27 (36%) of 75 children having NCSz. It was also found that comatose patients often required more than 24 hours of monitoring to detect the first electrographic seizure. Unfortunately, because of their limited and often subtle signs,4,9-11 NCSz are often underdiagnosed and as a result treated late in their course, potentially worsening the neurologic prognosis. In adults, diagnostic delays of up to 3 to 5 days were found in some studies in patients with NCSE.12,13 Furthermore, the longer recurrent NCSz or NCSE persist, the more difficult they are to treat and the higher the morbidity and mortality rates.14
- 1 December 2006
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 63 (12) , 1750-1755
Open AccessFrequency and Predictors of Nonconvulsive Seizures During Continuous Electroencephalographic Monitoring in Critically Ill Children
The epidemiologic features and understanding of nonconvulsive seizures (NCSz) and status epilepticus (SE) in critically ill patients is limited. However, accumulating evidence demonstrates that NCSz and nonconvulsive status epilepticus (NCSE) occur frequently in critical care patients. It is estimated that 19% to 50% of patients undergoing continuous electroencephalographic monitoring (cEEG) in neurologic and neurosurgical intensive care units (ICUs) may be experiencing NCSz or NCSE,1-6 with many of the NCSz occurring after supposedly adequate treatment for generalized convulsive status epilepticus (GCSE).4,7 One prospective study evaluated comatose patients in all age groups with no overt clinical seizure activity to determine how many had NCSE, and 8% met the criteria for this diagnosis.8 One retrospective study at our center examined a population of 570 critically ill patients, 13% of whom were children.5 In that study, seizures were detected in 19% of patients who underwent cEEG, and these were exclusively nonconvulsive in 92%. Age younger than 18 years was a risk factor for electrographic seizures, with 27 (36%) of 75 children having NCSz. It was also found that comatose patients often required more than 24 hours of monitoring to detect the first electrographic seizure. Unfortunately, because of their limited and often subtle signs,4,9-11 NCSz are often underdiagnosed and as a result treated late in their course, potentially worsening the neurologic prognosis. In adults, diagnostic delays of up to 3 to 5 days were found in some studies in patients with NCSE.12,13 Furthermore, the longer recurrent NCSz or NCSE persist, the more difficult they are to treat and the higher the morbidity and mortality rates.14
- 22 July 2002
- Published by Wiley
- No. 2,p. CD001417
Topiramate add-on for drug-resistant partial epilepsy
The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy. To evaluate the efficacy and tolerability of topiramate when used as an add-on treatment in patients with drug resistant partial epilepsy. (a) The Cochrane Library (1999 Issue 1); (b) The controlled trial register of the Cochrane Epilepsy Group; (c) Johnson and Johnson, makers of topiramate; (d) Experts in the field. Randomized placebo controlled add-on trials of topiramate in patients with drug resistant epilepsy. Two reviewers independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) side effects. Primary analyses were intention to treat. Summary odds ratios (OR) were estimated for each outcome. Dose response was evaluated in regression models. Six trials were included representing 743 randomized patients. Overall OR (95% CIs) for 50% or greater reduction in seizure frequency compared to placebo 4.06 (2.86-5.78). Dose regression analysis shows increasing efficacy with increasing dose, but found no advantage for doses over 400 mg per day. Global effectiveness: treatment withdrawal OR (95% CIs) compared to placebo 2.57 (1.65-4.00). Side effects: OR (99% CIs)compared to placebo, dizziness 1.99 (1.20-3.29); fatigue 2.52 (1. 47-4.32); nausea 2.84 (1.36-5.93); somnolence 2.89 (1.72-4.85) and 'thinking abnormally' 3.71 (2.02-6.80) were significantly associated with topiramate. Topiramate has efficacy as an add-on treatment in patients with drug resistant partial epilepsy. However, trials reviewed were of relatively short duration, and provide no evidence for the long term efficacy of topiramate. Results cannot be extrapolated to monotherapy or patients with other epilepsy types.
- 22 July 2002
- Published by Wiley
- No. 2,p. CD001417
Topiramate add-on for drug-resistant partial epilepsy
The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy. To evaluate the efficacy and tolerability of topiramate when used as an add-on treatment in patients with drug resistant partial epilepsy. (a) The Cochrane Library (1999 Issue 1); (b) The controlled trial register of the Cochrane Epilepsy Group; (c) Johnson and Johnson, makers of topiramate; (d) Experts in the field. Randomized placebo controlled add-on trials of topiramate in patients with drug resistant epilepsy. Two reviewers independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) side effects. Primary analyses were intention to treat. Summary odds ratios (OR) were estimated for each outcome. Dose response was evaluated in regression models. Six trials were included representing 743 randomized patients. Overall OR (95% CIs) for 50% or greater reduction in seizure frequency compared to placebo 4.06 (2.86-5.78). Dose regression analysis shows increasing efficacy with increasing dose, but found no advantage for doses over 400 mg per day. Global effectiveness: treatment withdrawal OR (95% CIs) compared to placebo 2.57 (1.65-4.00). Side effects: OR (99% CIs)compared to placebo, dizziness 1.99 (1.20-3.29); fatigue 2.52 (1. 47-4.32); nausea 2.84 (1.36-5.93); somnolence 2.89 (1.72-4.85) and 'thinking abnormally' 3.71 (2.02-6.80) were significantly associated with topiramate. Topiramate has efficacy as an add-on treatment in patients with drug resistant partial epilepsy. However, trials reviewed were of relatively short duration, and provide no evidence for the long term efficacy of topiramate. Results cannot be extrapolated to monotherapy or patients with other epilepsy types.